Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1249)	6/25/2000 3:45:00 PM
From: Pseudo Biologist	Respond to of 52153

MZ, you are correct, although they seem to have done something similar with their human anti-CD4 as well. The beauty of MEDX and ABGX's business models, which to a large extents justifies their valuations (struggling to stay on topic here -g-), is that their potentially very significant milestone and royalty revenues give them a lot of room for error in clinical projects in their own account. The danger, of course, is that people become "lazy" given this, and projects are not chosen as carefully, or pursued as vigorously, as when your life depends on them -- as is this case for almost every other company. The idea of creating these funky subsidiaries, while maddening for us "valuators", may make a good deal of business sense. For easier reference, here is a direct link to MEDX's pipeline description in their web page: medarex.com PB